In a recent study, researchers reached an innovative method of antibodies by integrating immune protein, which opens new horizons for understanding diseases -related proteins, and this may contribute to developing new treatments.
The study was conducted by researchers from the research center, Bernham Pribus in the United States and the International Pharmaceutical Company, Elie Lily, published in the Journal of Immunology, and wrote about Yurrick Alrt.
This study is a big step towards improving the method of developing antibodies, which are used to treat many diseases such as cancer, as well as use in medical diagnosis.
What is the immune proteins?
Immune proteins play a role in the functions of the immune system, whether in identifying antigens, coordinating immune response, or organizing interactions between immune cells. Antibody is one of the prominent examples of this protein.
The immune system produces antibodies in response to the presence of antigens, which is any substances that the body considers strange or harmful, such as viruses, bacteria, or exotic substances. The antibodies are working to identify the antigens and link them to disable them or facilitate their elimination by other immune cells.
In the medical and research field, monoclonal antibodies are widely used in the treatment of immune and cancerous diseases, as well as in diagnosing diseases and studying biological reactions within the body.
The unilateral antibodies are a special type of antibodies that are produced in the laboratory, which come from one immune cell, and are directed against one type of antigen, and are used in the treatment of many diseases such as cancer and immune diseases, as it is also used in the diagnosis of diseases and the study of biological processes in the body.
New innovation
The study focused on protein appearing on the surface of the immune cells. When they interact together, they form a complex protein compound that affects the strength of the immune system response.
Scientists have discovered that the percentage between free proteins (separately present) and the built -in compound (protein complex) may be important in diseases such as lupus, but it was difficult to measure their quantity.
To overcome this difficulty, the researchers have developed a new solution by creating a built -in protein that combines protein. This merging made proteins more stable, which allowed them to successfully generate unilateral antibodies. Then they identified which antibodies were the best in the bound to the built -in protein, and used these antibodies to compare the amounts of free and complex proteins in different immune cells.
This study was the first of its kind that shows the direct measurement of the protein compound on the living cells using an anti -protein body for this protein complex.
These results are useful in diagnosing and following diseases such as lupus and some types of cancer, such as lymphoma.